CBIO (Crescent Biopharma) FCF Margin %: -1,644.27% (As of Mar. 2026)


CBIO Crescent Biopharma Inc CBIO
10 GF Score
Price $18.56
! 2 Warning Signs
View Full Analysis

What is Crescent Biopharma FCF Margin %?

Crescent Biopharma CBIO +9.24% 10 FCF Margin % is -1,644.27% as of Mar. 2026. GuruFocus rates CBIO with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 959 Biotechnology companies, Crescent Biopharma ranks worse than 75.5% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Crescent Biopharma's Free Cash Flow for the three months ended in Mar. 2026 was $-17.08 Mil. Crescent Biopharma's Revenue for the three months ended in Mar. 2026 was $1.04 Mil. Therefore, Crescent Biopharma's FCF Margin % for the quarter that ended in Mar. 2026 was -1,644.27%.

As of today, Crescent Biopharma's current FCF Yield % is -15.19%.

The historical rank and industry rank for Crescent Biopharma's FCF Margin % or its related term are showing as below:

CBIO' s FCF Margin % Range Over the Past 10 Years
Min: -1332.08   Med: -1332.08   Max: -654.42
Current: -654.42

During the past 2 years, the highest FCF Margin % of Crescent Biopharma was -654.42%. The lowest was -1332.08%. And the median was -1332.08%.

CBIO's FCF Margin % is ranked worse than
75.5% of 959 companies
in the Biotechnology industry
Industry Median: -84.65 vs CBIO: -654.42

Crescent Biopharma FCF Margin % Related Terms

Crescent Biopharma FCF Margin % Historical Data

* Premium members only.

The historical data trend for Crescent Biopharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crescent Biopharma FCF Margin % Chart

Crescent Biopharma Annual Data
Trend Dec24 Dec25
FCF Margin %
0.00 -1,332.08

Crescent Biopharma Quarterly Data
Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial 0.00 0.00 0.00 -246.59 -1,644.27

CBIO vs RIGL, GYRE, TRAX: FCF Margin % Comparison

For the Biotechnology subindustry, Crescent Biopharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Crescent Biopharma FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Crescent Biopharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Crescent Biopharma's FCF Margin % falls into.


CBIO
10GF Score
Crescent Biopharma Inc CBIO
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Crescent Biopharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Crescent Biopharma's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-144.451/10.844
=-1,332.08 %

Crescent Biopharma's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-17.084/1.039
=-1,644.27 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -1,644.27% mean?
Crescent Biopharma (CBIO) has a FCF Margin % of -1,644.27% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Crescent Biopharma and its competitors. According to the industry distribution chart, Crescent Biopharma ranks #724 out of 959 companies in the Biotechnology industry, placing it in the top 75.5%.
Is Crescent Biopharma's FCF Margin % too high?
Crescent Biopharma's current FCF Margin % is -1,644.27%. Based on the distribution chart, Crescent Biopharma ranks #724 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Crescent Biopharma has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Crescent Biopharma's FCF Margin % compare to RIGL and GYRE?
According to the Biotechnology industry distribution chart, Crescent Biopharma ranks #724 out of 959 companies for FCF Margin %. This places Crescent Biopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Crescent Biopharma and its competitors. Crescent Biopharma's current FCF Margin % is -1,644.27%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescent Biopharma stock overvalued right now?
Crescent Biopharma (CBIO) has a current FCF Margin % of -1,644.27%. The current FCF Margin % is -1,644.27%. Crescent Biopharma's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Crescent Biopharma (CBIO), the current FCF Margin % is -1,644.27% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Crescent Biopharma Business Description

Other Exchanges C68:Germany
Address 300 Fifth Avenue, Waltham, MA, USA, 02451
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
10GF Score

Get the complete analysis for CBIO

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.56
Price